Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS

Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASClinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype.Of 2327 patients with KRAS-mutated (KRASKRAS